

The **C**hronic kidney disease **A**daptive
Platform **T**rial Investigating **V**arious **A**gents for
Therapeutic **E**ffect (**CAPTIVATE**)

Conflict of Interest Registry

Version 1.0

18 November 2024

1. Platform Oversight Committee

Investigator	Conflict of interest statement
A/Prof Sradha Kotwal	<p>Dr Kotwal reports the following: Consultancy: Chinook Pharmaceuticals and Dimerix Pharmaceuticals;</p> <p>Research Funding: The George Institute and its affiliated entities work with numerous health and pharmaceutical companies in the design, implementation and analyses of clinical research and clinical trials; and Advisory or Leadership Role: Dimerix Pharmaceuticals and Chinook Pharmaceuticals (steering committee member).</p>
Hiddo Lambers-Heerspink	<p>Prof Lambers Heerspink has received honoraria for participation in steering committees from AstraZeneca, Janssen, Eli-Lilly, Gilead, Bayer, Chinook, Novartis, and CSL Behring; honoraria for participation in advisory boards from AstraZeneca, Bayer, Boehringer Ingelheim, Novartis, NovoNordisk, and Idorsia; fees for consultancy from AstraZeneca, Traverre Therapeutics, Boehringer Ingelheim, and Novo Nordisk; and research grant support from AstraZeneca, Janssen, Boehringer Ingelheim and NovoNordisk. Honoraria for steering committee memberships and consultancies are paid to his employer.</p>

Vlado Perkovic

Prof Perkovic is employed by UNSW Sydney, and serves as a Board Director for St.Vincents Health Australia, and several Medical Research Institutes. Prof Perkovic has received honoraria for Steering Committee roles, scientific presentations and/or advisory board attendance from Abbvie, Amgen, Astra Zeneca, Bayer, Baxter, Boehringer Ingelheim, Chinook, Durect, Eli Lilly, Gilead, GSK, Janssen, Merck, Mitsubishi Tanabe, Mundipharma, Novartis, Novo Nordisk, Otsuka, Pharmalink, Pfizer, Reata, Travere, Relypsa, Roche, Sanofi, Servier and Tricida.

Ian de Boer

Prof de Boer has received consulting fees from AstraZeneca, Boehringer Ingelheim, and Lilly, and nonfinancial support from DexCom and Novo Nordisk.

Meg Jardine

Prof Jardine is supported by an Australian government NHMRC Investigator Grant; is responsible for research projects that have received funding from Amgen, Baxter, CSL, Dimerix, Eli Lilly, Gambro, Kensana and MSD; has received fees for Advisory, Steering Committee and/or Scientific Presentations from Akebia, Amgen, Astra Zeneca, Baxter, Bayer, Boehringer Ingelheim, Cesas Medical, Chinook, CSL, Janssen, Medcon International, Medscape, MSD, Occurx, Roche and Vifor; with any consultancy, honoraria or travel support directed to her institution.

Laurent Billot	Prof Billot has previously received lecture fees from Novo Nordisk.
Helen Monaghan	Dr Monaghan has nothing to disclose.
Enmoore Lin	Dr Lin has nothing to disclose.
Vivekanand Jha	Prof Jha has received grant funding from GSK, Baxter Healthcare and Biocon and honoraria and Consultancy Fees from GSK, Bayer, AstraZeneca, Boehringer Ingelheim, Visterra, Biocryst, Vera, Chinook, and Zydus Cadilla, under the policy of all monies being paid to the organisation.
Clare Arnott	A/Prof Arnott has received honoraria from Amgen, Novo Nordisk and AstraZeneca
Luca De Nicola	Prof De Nicola has received fees for scientific consultation and/or lectures by Amgen, Astellas, AstraZeneca, GSK, Mundibiopharma and Vifor Pharma.
Rathika Krishnasamy	A/Prof Krishnasamy has received consultancy/ honorarium from Baxter Healthcare and AstraZeneca; travel support from Amgen and Baxter Healthcare; and received funding for investigator-initiated research from Baxter Healthcare.
Vicki Grey	Vicki Grey is a member of the PREVENTS-AKI Global Streeting Committee and START Management Committee.
Dean Guinness	Has nothing to disclose
Gian Luca Di Tanna	Prof Di Tanna has nothing to disclose

2. MRA DSA Steering Committee

Committee member	Conflict of interest statement
Sradha Kotwal	As above
Hiddo Lambers-Heerspink	As above
Enmoore Lin	As above
Vivekanand Jha	As Above
Clare Arnott	As Above
Luca De Nicola	As above
Nicholas Gray	Dr Gray has direct share ownership in CSL, BlueScope Steel, L1 long short fund, and MFF Capital investments Ltd; Honoraria from AstraZeneca and BI/Eli Lilly.
Dana Kim	Dr Kim has nothing to disclose
Nasir Shah	Dr Shah has nothing to disclose
Janak de Zoysa	A/Prog de Zoysa has nothing to disclose